Robert W. Yeh et al. JACC 2017;70:

Slides:

Advertisements

Similar presentations

Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.

Advertisements

Individualizing Treatment Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Analysis from the DAPT Study Robert W. Yeh,

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,

DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.

Stenting of Coronary Arteries in Non Stress/Benestent Disease

Alan Rozanski et al. JACC 2005;45:

Stephen W. Waldo et al. JACC 2008;51:

Glenn N. Levine et al. JACC 2016;68:

Zhi-hui Hou et al. JIMG 2012;5:

Glenn N. Levine et al. JACC 2016;68:

Nat. Rev. Cardiol. doi: /nrcardio

Robert W. Yeh et al. JACC 2017;70:

Robert W. Yeh et al. JACC 2017;70:

Pablo Ávila et al. JACEP 2015;1:

Dean J. Kereiakes et al. JACC 2017;70:

Nat. Rev. Cardiol. doi: /nrcardio

Alexander Ghanem et al. JACC 2010;55:

3-Year Clinical Outcomes From the RESOLUTE US Study

Johannes Steiner et al. JACC 2017;70:

Peter K. Smith, MD The Journal of Thoracic and Cardiovascular Surgery

Peter K. Smith, MD The Annals of Thoracic Surgery

Belinda Gray et al. JCHF 2013;1:

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

(p = 0.32 for noninferiority)

FOR DISTRIBUTION BY MEDTRONIC OFFICE OF MEDICAL AFFAIRS ONLY.

John A. Bittl et al. JACC 2016;68:

Khurram Nasir et al. JACC 2015;66:

Konstantinos C. Siontis et al. JACEP 2016;2:

Vittorio Calzolari et al. JACEP 2017;3:

Kenshi Hayashi et al. JACEP 2016;2:

SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.

Brian R. Weil et al. BTS 2017;2: Experimental Protocol (A) Following baseline data collection, the left anterior descending coronary artery was.

Jennifer T. Thibodeau et al. JCHF 2014;2:24-31

Hampton A. Crimm et al. JACEP 2016;2:

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Roberta Rossini et al. JCIN 2018;11:

Peter E. Carson et al. JCHF 2015;3:

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

K.R. Julian Chun et al. JACEP 2017;3:

Jennifer T. Thibodeau et al. JCHF 2014;2:24-31

Seung-Yul Lee et al. JCIN 2018;j.jcin

Writing Committee Members et al. JACC 2018;j.jacc

Yusuke Watanabe et al. JCIN 2016;9:

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Jeffrey L. Anderson et al. JACC 2007;50:e1-e157

Glenn N. Levine et al. JACC 2011;58:e44-e122

Alan Rozanski et al. JIMG 2017;10:

Charanjit S. Rihal et al. JCIN 2012;5:

Lee A. Fleisher et al. JACC 2014;64:e77-e137

Stavros V. Konstantinides et al. JACC 2017;69:

Khadijah Breathett et al. JCHF 2017;5:

Maria Alejandra Restrepo-Cordoba et al. JCIN 2016;9:e137-e139

(A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus.

Gregory Piazza et al. JCIN 2015;8:

Davide Capodanno et al. JCIN 2009;2:

Matias B. Yudi et al. JACC 2018;71:

Matias B. Yudi et al. JACC 2018;71:

Rick A. Nishimura et al. JACC 2017;70:

Jeffrey Senfield et al. JACEP 2017;3:

Matias B. Yudi et al. JACC 2018;71:

James O. Mudd et al. JACC 2007;50:

Thomas A. Dewland et al. JACEP 2015;1:

American College of Cardiology/American Heart Association 2016 dual antiplatelet therapy (DAPT) focused update: Implications for surgeons Richard J.

Omar Abdul-Jawad Altisent et al. JCIN 2016;9:

James H O'Keefe, Jr et al. JACC 2004;43:

Federico Migliore et al. JIMG 2013;6:32-41

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Presentation transcript:

Robert W. Yeh et al. JACC 2017;70:2213-2223 Enrollment, Randomization, and Follow-Up of Subjects in the DAPT Study Stratified By Lesion Complexity Status Of 25,416 subjects enrolled in the DAPT (Dual Antiplatelet Therapy) study and with anatomic lesion complexity information available, 8,381 (33.0%) were found to have complex coronary lesions at the index procedure. *Subjects may have >1 event. **Site terminated participation, randomization target met prior to subject follow-up, or subject not recognized to be eligible by site. †Subjects moved, were incarcerated, or were prematurely exited from the study. GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. Robert W. Yeh et al. JACC 2017;70:2213-2223 2017 American College of Cardiology Foundation